

Aequus Pharmaceuticals Inc.

11:00 22 Sep 2020

Aequus Pharmaceuticals expands Medicom Healthcare partnership with additional formulation in its Evolve eye product line

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) announced Tuesday that it has expanded its partnership with UK-based Medicom Healthcare to include an additional formulation in its Evolve preservative-free dry eye product line.

Aequus recently submitted an application for this new product with Health Canada for processing of a New Medical Device License.

Vancouver-based Aequus said the new Evolve product added to the existing agreement is a unique preservative-free formulation. The product formulation combines Hyaluronate and Carbomer 980 for the treatment of patients with more intense dry eye symptoms.

READ: Aequus Pharmaceuticals files new medical device licenses for Evolve dry eye products in Canada

With the addition of this product to the Health Canada submission, Aequus said it plans to launch a full range of products designed to treat patients suffering from mild to more intensive forms of dry eye disease later in 2020.

"In preparation for launch, we have engaged Canadian eyecare professionals by creating advisory boards and research groups, built B2B relationships with clinic networks, added specialized personnel to our commercial team, and planned branded marketing campaigns to targeted customer segments," said Aequus CEO Doug Janzen in a statement.

"Our team has a deep understanding of ophthalmology and years of operational experience. We see our new product launches as being the perfect fit for Canadian patients who have been wanting a wider range of options for dry eye treatments. We are more than ready now, for the anticipated approval of these three Evolve products in Canada, that will be launching into a \$90 million dry eye market"

Aequus has now submitted three new products for Health Canada approval.

As with the previous submissions, the additional Evolve product was submitted for approval with Health Canada as a Class II medical device. According to Health Canada, the target review time for a Class II MDL application is typically 20 days.

Aequus is moving ahead with plans in accordance with this timeline but acknowledges that review timing may be affected by factors out of its control such as backlogs caused by COVID-19.

Contact the author: patrick@proactiveinvestors.com

Price: 0.11

Market Cap: \$12.29 m

1 Year Share Price Graph



Share Information

Code: AQS

Listing: TSX-V

52 week High Low
0.175 0.065

Sector: Pharma & Biotech

Website: www.aequuspharma.ca

Company Synopsis:

Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.

action@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).